'Hard to lose' mutations in tumors may predict response to immunotherapy
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy. Now, investigators at the Johns ...